登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《Cell，6月6日，Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-06-07

  • Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2

    Hui Wang ∗

    Yuntao Zhang ∗

    Baoying Huang ∗

    George Fu Gao †

    Wenjie Tan †

    Xiaoming Yang †

    Show all authors

    Show footnotes

    Published:June 06, 2020DOI:https://doi.org/10.1016/j.cell.2020.06.008

    Summary

    The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) threatens global public health. The development of a vaccine is urgently needed for the prevention and control of COVID-19. Here, we report the pilot-scale production of an inactivated SARS-CoV-2 vaccine candidate (BBIBP-CorV) that induces high levels of neutralizing antibodies titers in mice, rats, guinea pigs, rabbits and nonhuman primates (cynomolgus monkeys and rhesus macaques) to provide protection against SARS-CoV-2. Two-dose immunizations using 2 μg/dose of BBIBP-CorV provided highly efficient protection against SARS-CoV-2 intratracheal challenge in rhesus macaques, without detectable antibody-dependent enhancement of infection. In addition, BBIBP-CorV exhibits efficient productivity and good genetic stability for vaccine manufacture. These results support the further evaluation of BBIBP-CorV in a clinical trial.

  • 原文来源：https://www.cell.com/cell/fulltext/S0092-8674(20)30695-4
32浏览量
原文链接
相关报告

  • 《Science，7月3日，Development of an inactivated vaccine candidate for SARS-CoV-2》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-07-08
    • Development of an inactivated vaccine candidate for SARS-CoV-2 Qiang Gao1,*,Linlin Bao2,*, Haiyan Mao3,*, Lin Wang1,*, Kangwei Xu4,*, View ORCID ProfileMinnan Yang5,*, Yajing Li1 See all authors and affiliations Science 03 Jul 2020: Vol. 369, Issue 6499, pp. 77-81 DOI: 10.1126/science.abc1932 Abstract The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in an unprecedented public health crisis. Because of the novelty of the virus, there are currently no SARS-CoV-2–specific treatments or vaccines available. Therefore, rapid development of effective vaccines against SARS-CoV-2 are urgently needed. Here, we developed a pilot-scale production of PiCoVacc, a purified inactivated SARS-CoV-2 virus vaccine candidate, which induced SARS-CoV-2–specific neutralizing antibodies in mice, rats, and nonhuman primates. These antibodies neutralized 10 representative SARS-CoV-2 strains, suggesting a possible broader neutralizing ability against other strains. Three immunizations using two different doses, 3 or 6 micrograms per dose, provided partial or complete protection in macaques against SARS-CoV-2 challenge, respectively, without observable antibody-dependent enhancement of infection. These data support the clinical development and testing of PiCoVacc for use in humans.
    9浏览量
    原文链接

  • 《6月6日_北京生物制品研究所和中国疾控中心等中国团队Cell发文报道研制了一种抗SARS-CoV-2的新型灭活疫苗BBIBP-CorV》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-06-07
    • 信息名称：北京生物制品研究所和中国疾控中心等中国团队Cell发文报道研制了一种抗SARS-CoV-2的新型灭活疫苗BBIBP-CorV 1.时间：2020年6月6日 2.机构或团队：北京生物制品研究所有限责任公司、中国疾病预防控制中心病毒病预防控制所、新发再发传染病动物模型研究北京市重点实验室、国家人类疾病动物模型资源库、国家卫健委人类疾病比较医学重点实验室、中国医学科学院实验动物研究所、北京协和医学院比较医学中心、国家食品药品监督管理总局、清华大学等 3.事件概要： 6月6日，Cell发表了题为“Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2”的文章。 由SARS-CoV-2引起的COVID-19大流行威胁着全球公共健康。为了预防和控制COVID-19，迫切需要研制一种疫苗。在本文中报道了一种SARS-CoV-2灭活候选疫苗（BBIBP-CorV）的中试生产，该疫苗能诱导小鼠、大鼠、豚鼠、兔子和非人灵长类动物（食蟹猴和恒河猴）产生高水平的中和抗体滴度，以实现对SARS-CoV-2的保护。2μg/剂量的双剂量BBIBP-CorV免疫可使恒河猴具有高效的抗SARS-CoV-2气管内感染保护作用，且无明显的抗体依赖性感染增强。此外，BBIBP-CorV在疫苗生产中表现出高效的生产效率和良好的遗传稳定性。以上这些结果支持BBIBP-CorV在临床试验中的进一步评价。 4.附件： 原文链接 https://www.cell.com/cell/fulltext/S0092-8674(20)30695-4
    118浏览量
    原文链接